Akari Therapeutics PLC ADR 2026年季度报告

FORM 10-Q (Mark One) For the quarterly period ended March 31, 2026 OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Commission File Number 001-36288 Akari Therapeutics, Plc(Exact name of registrant as specified in its charter) 98-1034922(I.R.S. EmployerIdentification No.) England and Wales(State or other jurisdiction ofincorporation or organization) Registrant’s telephone number, including area code: (929) 274-7510 Securities registered pursuant to Section 12(b) of the Act: * Trading, but only in connection with the American Depositary Shares. Indicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports),and (2) has been subject to such filing requirements for the past 90 days. Yes☒No☐ Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that theRegistrant was required to submit such files). Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reportingcompany, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reportingcompany,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. Large accelerated filer Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). YES☐NO☒ The number of shares of Registrant’s Ordinary Shares outstanding as of May 19, 2026, was 91,567,009,533. TABLE OF CONTENTS PagePART IFINANCIAL INFORMATION1Item 1.Financial Statements (Unaudited)1Condensed Consolidated Balance Sheets1Condensed Consolidated Statements of Operations and Comprehensive Loss2Condensed Consolidated Statements of Changes in Shareholders’ Equity3Condensed Consolidated Statements of Cash Flows4Notes to Unaudited Condensed Consolidated Financial Statements5Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations18Item 3.Quantitative and Qualitative Disclosures About Market Risk26Item 4.Controls and Procedures27PART IIOTHER INFORMATION28Item 1.Legal Proceedings28Item 1A.Risk Factors28Item 2.Unregistered Sales of Equity Securities and Use of Proceeds28Item 3.Defaults Upon Senior Securities28Item 4.Mine Safety Disclosures28Item 5.Other Information28Item 6.Exhibits28SIGNATURES29i GENERAL INFORMATION Unless otherwise stated or the context requires otherwise, references in this Quarterly Report on Form 10-Q (“Form 10-Q”) to“Akari,” the “company,” the “Company,” “we,” “us,” “our” or similar designations refer to Akari Therapeutics, Plc and itssubsidiaries, taken together. All trademarks, service marks, trade names and registered marks used in this report are trademarks, tradenames or registered marks of their respective owners. Statements made in this Form 10-Q concerning the contents of any agreement, contract or other document are summaries of suchagreements, contracts or documents and are not complete description of all of their terms. If we filed any of these agreements,contracts or documents as exhibits to this Form 10-Q or to any previous filing with the Securities and Exchange Commission (“SEC”),you may read the document itself for a complete understanding of its terms. NOTE REGARDING FORWARD-LOOKING STATEMENTS This Form 10-Q and the documents we incorporate by reference contain forward-looking statements within the meaning of Section27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, asamended (the “Exchange Act”). All statements, other than statements of historical fact, included or incorporated in this reportregarding, among other things, our cash resources and projected cash runway, financial position, our strategy, strategic alternatives,future operations, clinical trials (including, without limitation, the anticipated timing enrollment, and results thereof), collaborations,intellectual property, future revenues, projected costs, fundraising and/or financing plans, prospects, developments relating to ourcompetitors and our industry, the timing or likelihood of regulatory actions, filings and approvals for our current and future drugcandidates, and the plans and objectives of management are forward-loo